Glaukos Corporation

NYSE:GKOS

Medical - Devices

Healthcare
$233.08 -0.14%

-$0.18 today

Market cap
$13.80B
Beta
0.81
P/E (TTM)
-39.0
EPS (TTM)
-$3.26
52W Low $73.16High $148.11

Volume 1.12M

Average 0.94M

GKOS Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Glaukos CorporationNYSE: GKOS

Effect of Forex Changes · Q2 FY2026 · quarter ended Jun 2026

Effect of forex changes dips below year-ago levels

Q2 FY2026 effect of forex changes of $991K (cash outflow) fell 64.4% year over year, behind the +167.4% change in trailing-twelve-month effect of forex changes. Sequentially, it rose 218.6% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Effect of forex changes amounted to 0.2% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -64.4% toward the trailing-twelve-month pace of +167.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$991K+218.6% QoQ
Last fiscal yearDec 2025
$804K+142.4% YoY
LTMJun 2026
$4.14M+167.4% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.4%——
1 year+142.4%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
804K USD
Year-over-year change
+142.4%

Effect of Forex Changes vs competitors

How GKOS compares with its peers on the latest reported figures

  • GKOS's LTM Jun 2026 effect of forex changes of $4.14M is the 3rd largest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of +167.4% is the 2nd highest of 5, against a peer median of -11.4%.
  • Effect of forex changes amounts to 0.7% of revenue for GKOS, versus a peer median of 0.0%.
GKOS Competitors Peer median
Effect of Forex Changes for GKOS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALCAlcon Inc.LTM Sep 2026$13.1M -187.2%-11.0%0.1%
BLCOBausch + Lomb CorporationLTM Jun 2026$5.48M -122.8%—0.1%
GKOSGlaukos CorporationLTM Jun 2026$4.14M +167.4%-2.6%0.7%
STAASTAAR Surgical CompanyLTM Apr 2026$1.11M +887.5%—0.4%
SGHTSight Sciences, Inc.LTM Mar 2026$2K ——0.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 ——0.0%
SGPSpyGlass Pharma, Inc. Common StockFY2025$0 ———
RXSTRxSight, Inc.LTM Mar 2026$0 +100.0%—0.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding GKOS) $0-11.4%-11.0%0.0%

Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.59M)(99.2M)(134.66M)(146.37M)(133.66M)
Depreciation & Amortization34.42M35.95M37.98M39.92M42.35M
Deferred Income Tax(1.03M)(54K)(120K)(216K)(6.49M)
Stock-Based Compensation30.15M38.56M43.53M50.21M63.22M
Change in Working Capital3.58M(13.45M)(10.13M)(39.47M)(31.55M)
Accounts Receivables1.7M(3.14M)(3.84M)(21.97M)(53.02M)
Inventory(7.7M)(15.47M)(4.83M)(18.79M)2.65M
Accounts Payables12.45M7.21M1.31M21K18.82M
Other Working Capital(2.87M)(2.05M)(2.77M)1.26M0
Other Non-Cash Items7.19M5.11M5.65M34.62M19.79M
Operating Cash Flow24.71M(33.08M)(57.76M)(61.32M)(46.34M)
Capital Expenditures(47.79M)(30.27M)(20.25M)(6.3M)(7.67M)
Acquisitions (Net)3K151K038K(12.44M)
Purchases of Investments(215.29M)(59.26M)(265.59M)(189.96M)(232.29M)
Sales of Investments206.92M135.16M303.1M247.2M196.94M
Other Investing Activities(2.08M)(1.01M)(3.17M)(3.15M)(22.16M)
Investing Cash Flow(58.23M)44.78M14.1M47.83M(77.61M)
Debt Repayment(659K)(527K)(711K)51.34M(1.12M)
Common Stock Issued30.94M9.21M19.03M46.76M21.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.98M(2.43M)(3.27M)(6.56M)(8.13M)
Financing Cash Flow39.26M6.25M15.04M91.54M11.89M
Effect of Forex Changes(1.62M)870K2.56M(1.89M)804K
Net Change in Cash4.11M18.82M(26.06M)76.16M(111.26M)
Free Cash Flow(23.08M)(63.35M)(78.01M)(67.62M)(54.01M)

Glaukos Corporation

NYSE:GKOS

Intrinsic Alpha fair value

Locked

Current Price

$233.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.